Baxdrostat Alternatives: How It Compares to Other Aldosterone-Targeted Therapies

Baxdrostat vs Eplerenone (Inspra)

No head-to-head Phase-3 trial directly compares Baxdrostat with Eplerenone.

Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.

Baxdrostat vs Finerenone (Kerendia)

No head-to-head Phase-3 trial directly compares Baxdrostat with Finerenone.

Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.

Baxdrostat vs Aprocitentan (Tryvio)

No head-to-head Phase-3 trial directly compares Baxdrostat with Aprocitentan.

In separate pivotal trials, Baxdrostat reported 9.8mmHg Placebo-adjusted reduction in seated systolic blood pressure at 12 weeks (NCT06034743) versus -3.8mmHg Placebo-adjusted change in sitting systolic blood pressure at 4 weeks for Aprocitentan (NCT03541174).

Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.

Investigational agents in active Phase 3 development include Finerenone and Vicadrostat. Finerenone, with an unknown sponsor, is a non-steroidal mineralocorticoid receptor antagonist. Vicadrostat, also with an unknown sponsor, is an aldosterone synthase inhibitor.

Compared to Baxdrostat, which is an aldosterone synthase inhibitor, Vicadrostat shares a similar mechanism of action. Finerenone, however, represents a different approach as a mineralocorticoid receptor antagonist.

Baxdrostat, as an aldosterone synthase inhibitor, offers a distinct mechanism of action compared to other therapies targeting the renin-angiotensin-aldosterone system. This direct inhibition of aldosterone synthesis differentiates it from mineralocorticoid receptor antagonists such as eplerenone and finerenone, which block the receptor, and from endothelin receptor antagonists like aprocitentan.

When considering alternatives, therapies with different mechanisms may be preferred depending on specific patient needs. Eplerenone (Inspra) and finerenone (Kerendia) are mineralocorticoid receptor antagonists, offering a different approach to aldosterone modulation. Eplerenone is dosed at 50 mg once daily for hypertension, potentially increasing to 50 mg twice daily, and 25 mg once daily, titrating to 50 mg once daily, for heart failure post-myocardial infarction. Finerenone is available in 10 mg, 20 mg, or 40 mg once daily formulations. Aprocitentan (Tryvio), an endothelin receptor antagonist, demonstrated a placebo-adjusted change in sitting systolic blood pressure of -3.8mmHg at 4 weeks when dosed at 12.5 mg once daily. These options provide varying mechanisms and dosing regimens that may align with different clinical presentations or treatment goals.

Ultimately, the choice of therapy is a complex clinical decision that should be made by the prescriber in consultation with the patient, considering individual patient characteristics, comorbidities, and treatment goals.